Knight study on multiple myeloma supports new standard of treatment
A new study, published in the New England Journal of Medicine, found that 63 percent of multiple myeloma patients have a reduced risk of disease progression or death if treated with lenalidomide (Revlimid®) following a stem cell transplant. The study was co-authored by Richard Mariarz, MD, medical director of the Adult Stem Cell Transplantation Program & Center for Hematologic Malignancies at the Knight Cancer Institute.
Read the OHSU News Release to learn more.
Recent Comments
- Quen on Phillip Marucha, D.M.D., Ph.D., is new School of Dentistry dean
- Sandy Pierce on Doernbecher researchers first to grow transplantable liver stem cells in culture
- Susan Oliver on 125th lecture series: Eric Dishman on accelerating personal health, April 1
More Comments